Last reviewed · How we verify

Topiramate Standard

Janssen Korea, Ltd., Korea · FDA-approved active Small molecule

Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability.

Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability. Used for Epilepsy / seizure disorders, Migraine prophylaxis, Bipolar disorder (off-label).

At a glance

Generic nameTopiramate Standard
SponsorJanssen Korea, Ltd., Korea
Drug classAnticonvulsant / Antiepileptic agent
TargetVoltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Topiramate is a sulfamate-substituted monosaccharide that acts through multiple mechanisms: it blocks voltage-gated sodium channels, potentiates GABA-A receptor activity, and inhibits carbonic anhydrase. These combined effects reduce neuronal firing and synaptic transmission, making it effective for seizure suppression and migraine prevention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results